Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2002; 88(02): 354-355
DOI: 10.1055/s-0037-1613210
DOI: 10.1055/s-0037-1613210
Letters to the Editor
Effect of Factor XIII VAL34LEU Polymorphism on Thrombolytic Therapy in Premature Myocardial Infarction
Further Information
Publication History
Received
16 December 2001
Accepted after resubmission
26 April 2002
Publication Date:
07 December 2017 (online)
-
References
- 1 Lai E. Application of SNP technologies in medicine: lessons learned and future challenges. Genome Res 2001; 11: 927-9.
- 2 Dirckx C, Donati MB, Iacovello L. Pharmacogenetics: a molecular sophistication or a new clinical tool for cardiologist?. Ital Heart J 2000; 01: 662-6.
- 3 Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res 1999; 94: 271-305.
- 4 Wartiovaara U, Mikkola H, Szöke G, Haramura G, Kárpáti L, Balogh I, Lassila R, Muszbek L, Palotie A. Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A. Thromb Haemost 2000; 84: 595-600.
- 5 Ariëns RAS, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-95.
- 6 Kohler HP, Stickland MH, Ossei-Gernig N, Carter A, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79: 8-13.
- 7 Wartiovaara U, Perola M, Mikkola H, Tötterman K, Savolainen V, Penttilä PJGrant, Tikkanen MJ, Vartiainen E, Karhunen PJ, Peltonen L, Palotie A. Association of FXIII Va34Leu with decrease risk of myocardial infarction in Finish males. Atherosclerosis 1999; 142: 295-300.
- 8 Canavy I, Henry M, Morange PE, Tiret L, Poirier O, Ebagosti A, Bory M, Juhan-Vague I. Genetic polymorphism and coronary artery disease in the South of France. Thromb Haemost 2000; 83: 212-6.
- 9 Corral J, González-Conejero R, Iniesta JA, Rivera J, Martínez C, Vicente V. The FXIII Val34Leu polymorphism in venous and arterial thromboembolism. Haematologica 2000; 85: 293-7.
- 10 Warner D, Mansfield MW, Grant PJ. Coagulation factor XIII and cardiovascular disease in UK Asian patients undergoing coronary angiography. Thromb Haemost 2001; 85: 408-11.
- 11 Yusuf S, Collins R, Peto R. et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction. Overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 1985; 06: 556-85.
- 12 White HD, Norris RM, Brown MA. et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987; 317: 850-5.
- 13 Galvani M, Ottani F, Ferrini D, Sorbello F, Rusticali F. Patency of the infarct-related artery and left ventricular function as the major determinants of survival after Q-wave acute myocardial infarction. Am J Cardiol 1993; 71: 1-7.
- 14 Armstrong PW, Collen D. Fibrinolysis for acute myocardial infarction. Current status and new horizons for pharmacological reperfusion, Part 1. Circulation 2001; 103: 2862-6.
- 15 Bergmann SR, Sobel BE. Noninvasive assessment of the efficacy of coronary thrombolysis. In Thrombolysis in cardiovascular disease. Julian D, Kübler W, Norris RM, Swan HJC, Collen D, Verstraete M. eds. New York: Marcell Dekker; 1989: 141-61.